Consensus Healthcare Realty Trust Nyse

Equities

HR

US4219461047

Real-time Estimate Cboe BZX 03:57:40 2024-03-28 pm EDT 5-day change 1st Jan Change
14.16 USD +1.61% Intraday chart for Healthcare Realty Trust +5.05% -41.87%

Evolution of the average Target Price on Healthcare Realty Trust

Price target over the last 5 years

History of analyst recommendation changes

bf84e618a5259.LHnhE5Ef7Vp5RcEwSKNSUEx6mhx-XmvOk4bqjK9Ok3M.VS6kR9BvjhA0dpJHefw_H3wA9X4sOzH96u3dyvcFwTFfSZBw_nmVOB4yhA~d5bae72b883bbc29d33cf93d64fb5b13
Citigroup Cuts Healthcare Realty Trust Price Target to $13 From $17.50, Maintains Neutral Rating MT
JPMorgan Cuts Price Target on Healthcare Realty Trust to $17 From $19, Maintains Overweight Rating MT
Stifel Downgrades Healthcare Realty Trust to Hold Form Buy, Price Target is $15 MT
Wedbush Downgrades Healthcare Realty Trust to Neutral From Outperform, Says Up Against Elevated Investor Scrutiny With Slim Margin for Error in Near-Term; Adjusts PT to $15 From $19 MT
Deutsche Bank Initiates Coverage on Healthcare Realty Trust With Hold Rating, $18 Price Target MT
Wells Fargo Trims Price Target on Healthcare Realty Trust to $16 From $17, Maintains Equalweight Rating MT
BTIG Upgrades Healthcare Realty Trust to Buy From Neutral, Price Target is $17 MT
JPMorgan Upgrades Healthcare Realty Trust to Overweight From Neutral, Price Target is $19 MT
Scotiabank Cuts Healthcare Realty Trust's Price Target to $17 From $19, Maintains Sector Perform Rating MT
Wells Fargo Adjusts Healthcare Realty Trust's Price Target to $17 From $19, Equalweight Rating Kept MT
BMO Capital Cuts Price Target on Healthcare Realty Trust to $17 From $20, Keeps Market Perform Rating MT
Wedbush Starts Healthcare Realty Trust at Outperform With $17 Price Target MT
Citigroup Adjusts Price Target on Healthcare Realty Trust to $17 From $19, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Healthcare Realty Trust to $24 From $25, Maintains Overweight Rating MT
Barclays Adjusts Price Target on Healthcare Realty Trust to $25 From $24, Keeps Overweight Rating MT
Healthcare Realty Trust's First Q1 Normalized FFO Since Merger With Healthcare Trust of America Beats Analysts' Expectations MT
Barclays Adjusts Price Target on Healthcare Realty Trust to $24 From $28, Maintains Overweight Rating MT
Credit Suisse Downgrades Healthcare Realty Trust to Neutral From Outperform, Lowers Price Target to $20 From $23 MT
Fitch Affirms Healthcare Realty Trust at 'BBB'; Outlook Stable AQ
Citigroup Downgrades Healthcare Realty Trust to Neutral From Buy, Adjusts Price Target to $20 From $22.50 MT
JPMorgan Chase Adjusts Price Target on Healthcare Realty Trust to $22 From $28, Maintains Neutral Rating MT
Citigroup Upgrades Healthcare Realty Trust to Buy From Neutral, Adjusts Price Target to $28 From $27 MT
SMBC Nikko Upgrades Healthcare Realty Trust to Outperform From Neutral, Adjusts Price Target to $30 From $35 MT
Citigroup Reinstates Healthcare Realty Trust at Neutral With $27 Price Target MT
Healthcare Realty Trust Incorporated Announces Pro-Rated Quarterly Dividend, Payable on August 30, 2022 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
13.94 USD
Average target price
16.78 USD
Spread / Average Target
+20.36%
High Price Target
20 USD
Spread / Highest target
+43.47%
Low Price Target
13 USD
Spread / Lowest Target
-6.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Healthcare Realty Trust

Citigroup
JPMorgan Chase
Stifel Nicolaus
Wedbush
Deutsche Bank Securities
Wells Fargo Securities
BTIG
Scotiabank
BMO Capital
Barclays
Credit Suisse
SMBC Nikko
Raymond James
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings